The country’s hospitals are running out of treatment drug Sotrovimab. A remedy that effectively prevents admissions with the omicron variant.
This is what Jan Gerstoft, professor at the University of Copenhagen and chief physician at the Department of Infectious Diseases at Rigshospitalet, says. to DR’s Orientering on P1.
Currently, there are only 850 treatments with the product left at the Capital Region’s Pharmacy, which is the country’s largest. From here, medicines are delivered to the country’s hospitals.
“Right now we have relatively little. This means that we are starting to reduce consumption so that only patients at the highest risk can get it, “says Jan Gerstoft.
“It is definitely a problem, because we would like to give it to as many people as possible, but we do not have the opportunity to do that right now.
Sotrovimab is in high demand because it has been shown to be effective against omicron, says Jan Gerstoft.
Several other antibody treatments that have been useful earlier in the pandemic do not work against the new variant.
The drug is given early in a course of coronavirus. It works by injecting antibodies into the bloodstream. It is given to people who, for example, have a weakened immune system and therefore do not produce enough antibodies during vaccination.
“Studies have shown that the treatment can prevent hospitalizations by 85 percent,” says Jan Gerstoft.
New delivery in January
The Capital Region of Denmark has now been forced to prioritize who can receive treatment with Sotrovimab due to the lack.
Unvaccinated pregnant women are basically no longer offered the treatment, which they otherwise were previously in the region.
However, the other four regions inform DR that they continue to offer the treatment to unvaccinated pregnant women.
Jan Gerstoft expects new deliveries of Sotrovimab in mid-January. Both the Danish Medicines Agency and the medicine supplier Amgros are on Christmas holiday and have not been able to state the expected delivery time to DR.
Source: Politiken.dk – Forsiden by politiken.dk.
*The article has been translated based on the content of Politiken.dk – Forsiden by politiken.dk. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!
*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.
*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!